Treasury Departments Office of Foreign Assets Control (OFAC)

Tirzepatide Read the full profile Receptors activated (GIP + GLP-1 (dual)) Molecular weight (4,813.45 Da) Half-life (~5 days) Average weight loss (SURMOUNT-5, 72 wk) (~20%) Typical starting dose (2.5 mg/week) Typical maintenance dose (515 mg/week) Titration schedule (+2.5 mg every 4 weeks) Given as a weekly shot Available forms (Injection only) FDA-approved (Mounjaro/Zepbound) Brand-name price (no insurance) ($1,000+/month) Compounded price (where available) ($125$278/month) Shared GI side effects (nausea, etc.) Approved for sleep apnea Semaglutide Read the full profile Receptors activated (GLP-1 only) Molecular weight (4,113.64 Da) Half-life (~7 days) Average weight loss (STEP 1, 68 wk) (~15%) FDA-approved for cardiovascular risk reduction Typical starting dose (0.25 mg/week) Typical maintenance dose (2.4 mg/week) Titration schedule (+0.250.5 mg every 4 weeks) Given as a weekly shot Available forms (Injection or oral tablet (Rybelsus)) FDA-approved (Ozempic/Wegovy) Brand-name price (no insurance) ($1,000+/month) Compounded price (where available) ($99$178/month) Shared GI side effects (nausea, etc.) Our top-rated vendor Our rankings are based solely on third-party lab testing rigor, COA transparency, and pricing no paid placements, no affiliate influence

Diabetes Obes Metab 25:19321941 Knop FK, Aroda VR, Do Vale RD et al (2023) Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
p = 0.52 for interaction between subjects with established CVD vs risk factors only) (Fig